Focused Ultrasound for Neuropathic Pain

Recruiting in Palo Alto (17 mi)

Dr. Sheldon Jordan | Neurologist | Los ...

Overseen bySheldon Jordan, MD

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Academic

Waitlist Available

Sponsor: Neurological Associates of West Los Angeles

No Placebo Group

Approved in 2 Jurisdictions

Trial Summary

What is the purpose of this trial?This trial is testing a new treatment that uses sound waves directed at specific parts of the brain to help reduce pain. It targets patients with ongoing neuropathic pain that hasn't been managed well by other treatments. The sound waves aim to improve the function of brain areas that process pain signals. This noninvasive treatment option has shown promise in treating chronic neuropathic pain.

Eligibility Criteria

This trial is for adults who have ongoing neuropathic pain, confirmed by imaging or sensory signs, and haven't found relief after trying at least three different medications like antidepressants, anticonvulsants, or opioids. It's not suitable for those unable to consent, stay still during treatment, pregnant or breastfeeding women, or individuals with scalp conditions.

Inclusion Criteria

I am 18 years old or older.

I have tried at least 3 different medications for my condition without success.

I have experienced nerve pain, including when it started, where it hurts, how bad it is, how long it lasts, what it feels like, and what makes it worse.

+1 more

Exclusion Criteria

I have a scalp rash or open wounds on my scalp.

Pregnancy, women who may become pregnant or are breastfeeding

I cannot stay still when lying down in a calm environment.

+1 more

Participant Groups

The study tests focused ultrasound technology on the VPM and VPL thalamic nuclei in the brain as a potential treatment for neuropathic pain. The goal is to see if this non-invasive method is tolerable and shows early signs of effectiveness in reducing pain symptoms.

1Treatment groups

Experimental Treatment

Group I: ActiveExperimental Treatment1 Intervention

Patients will undergo ten to thirty minutes of transcranial ultrasound treatment. The sonification device will be aimed at the thalamus. Targeting will include reference to scalp fiducials based on the obtained MRI; confirmation of target accuracy will either be obtained by Doppler waveform confirmation or optical tracking technology which co-registers patient neuroimaging with real space.

Focused Ultrasound is already approved in United States, European Union for the following indications:

🇺🇸 Approved in United States as Gemzar for: